ϩ ions and CO2 on hypoxic sensitivity in humans. We also examined whether hypoxic sensitivity, conventionally defined as the ratio of (hypoxic Ϫ normoxic) ventilation over (hypoxic Ϫ normoxic) Hb oxygen saturation can also be estimated by taking the ratio (hypoxic Ϫ normoxic) ventilation over (logPa O 2 hypoxia Ϫ logPa O 2 normoxia), enabling one to measure the hypoxic response independently from potential confounding influences of changes in position of the Hb oxygen saturation curve. We used acetazolamide to induce a metabolic acidosis. To determine the acute hypoxic response (AHR), we performed step decreases in end-tidal PO2 to ϳ50 Torr lasting 5 min each at three different constant end-tidal PCO2 levels. Nine subjects ingested 250 mg of acetazolamide or placebo every 8 h for 3 days in a randomized double-blind crossover design. The metabolic acidosis was accompanied by a rise in ventilation, a substantial fall in Pa CO 2 , and a parallel leftward shift of the ventilatory CO 2 response curve. In placebo, CO2 induced equal relative increases in hypoxic sensitivity (O 2-CO2 interaction) regardless of the way it was defined. Acetazolamide shifted the response line representing the relationship between hypoxic sensitivity and arterial
THE HYPOXIC VENTILATORY RESPONSE in humans is biphasic and consists of an initial rise in ventilation initiated by the carotid bodies followed by a secondary roll-off, usually designated as hypoxic ventilatory decline (HVD) (8, 13, 16, 25) . The magnitude of this decline is proportionally related to the initial rise in ventilation in response to acute hypoxia and thus also to the intensity of the hypoxic stimulus (8, 18, 25) . Measurement of the ventilatory response to hypoxia without the "confounding" influence of HVD is possible by exposing subjects to brief step-wise changes in end-tidal PO 2 lasting 3-5 min, a period too short for HVD to develop. Consequently, the ventilatory response to such an acute hypoxic challenge (the acute hypoxic response, AHR) is attributed to the peripheral chemoreceptors in the carotid bodies. The magnitude of the AHR can be influenced by many factors such as the background arterial PCO 2 . A rise in Pa CO 2 augments the AHR, and this is known as multiplicative O 2 -CO 2 interaction (6, 7, 10) . This phenomenon is thought to reside in the carotid bodies (15, 22, 26) , but its mechanism at the molecular level in oxygen-sensitive type I cells remains to be elucidated (29) . A rise in Pa CO 2 not only leads to extracellular acidosis (acidemia) but also to increases in PCO 2 and [H] in carotid body cells. The relative contribution of these three changes during hypercapnia to the increase in carotid body activity remains a controversial issue, some studies suggesting a specific effect of the extracellular (i.e., arterial) pH supporting virtually no effect of molecular CO 2 (12, 19, 23, 44) , whereas others showed carotid body stimulation by CO 2 at constant extracellular pH (2, 14) or type I cell activation by both isocapnic changes in external pH and CO 2 (4) .
In humans, the interaction between hypoxia and metabolic acidosis and/or hypercapnia has been ascribed to a unique effect of arterial [H ϩ ] on hypoxic sensitivity (17, 24) . However, metabolic acidosis does not always lead to an augmented hypoxic response. For example, the carbonic anhydrase inhibitors acetazolamide and benzolamide produce a metabolic acidosis without increasing the isocapnic AHR (20, 37, 38, 43) . Apart from a substantial acidemia, acetazolamide also causes a substantial drop in arterial PCO 2 induced by a carotid bodymediated rise in ventilation (35, 38, 41) . When the Pa CO 2 is kept at the much higher pre-drug resting value, the AHR after acetazolamide becomes higher than control (43) . These findings suggest that unless these carbonic anhydrase inhibitors have specific effects on the carotid bodies, arterial H ϩ and CO 2 may have independent effects on the AHR. The aim of this study was to reinvestigate this issue. To quantify the O 2 -CO 2 interaction on ventilation, we measured the AHR at three levels of constant arterial PCO 2 in healthy volunteers after placebo and after induction of a metabolic acidosis with acetazolamide. In both placebo and metabolic acidosis, we determined the relationship between hypoxic sensitivity and the measured arterial [H ϩ ] at these three CO 2 levels. Due to the linear relationship between ventilation and arterial hemoglobin oxygen saturation, hypoxic sensitivity is usually expressed as the ratio delta ventilation over delta saturation (31, 32) . A potential problem, however, with metabolic acidosis is that the Hb saturation curve may shift to the right (Bohr effect) so that the ratio ⌬ ventilation/⌬ Sa O 2 may underestimate "true" hypoxic sensitivity, due to the fact that, at the level of arterial blood, the Pa O 2 rather than Sa O 2 represents the stimulus to the carotid bodies (21, 30) . Therefore, in this regard, it would be preferable to express hypoxic sensitivity with the aid of a parameter directly derived from the measured arterial PO 2 . In the cat, it has been demonstrated that in the hypoxic range, ventilation is a linear function of log Pa O 2 (Ref. 33 ; also Teppema, unpublished observations). In this study, we examined whether it would be justified to use the ratio delta ventilation over delta log Pa O 2 (in the range below 100 Torr) to determine relative increases in hypoxic sensitivity induced by alterations in arterial PCO 2 . To this aim, both in the placebo condition and following acetazolamide, hypoxic sensitivity was either defined in the conventional way, namely as the ratio ⌬ventilation/ ⌬Sa O 2 , or as the ratio ⌬ventilation/⌬log Pa O 2 , and CO 2 -induced relative increases in sensitivities were compared. In the placebo condition, both scenarios yielded almost identical outcomes, suggesting that a realistic estimation of changes in hypoxic sensitivity can be made without possible confounding effects of changes in saturation.
METHODS

Subjects and apparatus.
Nine healthy volunteers (ages 20 -23 yr; 4 men; 5 women using contraceptives) participated in this study after approval from the Leiden University Medical Centre human ethics committee. Written informed consent was obtained from all subjects, and the protocol was performed conforming to standards in the latest version of the Declaration of Helsinki. Throughout the testing schedule, subjects were instructed to abstain from caffeine and alcohol. On test days, a catheter was inserted into the right antecubital vein for infusion of a bicarbonate solution and into the left radial artery for arterial blood gas analysis and continuous blood pressure measurement.
Details of measuring ventilation, respiratory gases, and oxygen saturation and the technique of dynamic end-tidal forcing are provided elsewhere (40, 41) .
Study design. Following a randomized crossover double-blind design, subjects ingested either acetazolamide (250 mg/dose) or placebo every 8 h for 3 days ending the morning of outcome measurements. Each treatment period was separated by a 14-day washout period to overcome potential crossover effects of acetazolamide. On test days, 4 h after the last dose was taken, resting ventilation, blood pressure, end-tidal PO 2 and PCO2 (PET O 2 and PET CO 2 ), and arterial acid base and electrolyte status were measured. Subsequently, the following protocols were performed.
Experiments in hyperoxia, normoxia, and hypoxia. At three different levels of constant PET CO 2 , we first followed a protocol aimed to determine steady-state ventilation in normoxia and mild hyperoxia after the subjects were exposed to a 5-min bout of hypoxia. First, subjects breathed quietly in normoxia (PET O 2 100 -110 Torr) at a PET CO 2 2-3 Torr above resting (level 1). After ϳ6 min, PET O 2 was increased to ϳ150 Torr for 5-8 min and then lowered stepwise to 49 -50 Torr for 5 min to enable the AHR to develop. The hypoxic exposures were limited to 5 min to prevent HVD from developing (e.g., see Ref. 8) . Arterial samples were collected at the end of the normoxic and hypoxic periods. Hypoxia was terminated by returning to mild hyperoxia (PET O 2 ϳ 150 Torr) for 5 min, at which time the subjects breathed room air for 15 min. This procedure was repeated at constant PET CO 2 values that were higher than level 1 by 2-3 Torr (level 2) and 4 -6 Torr (level 3), respectively. This whole sequence was repeated after infusion of bicarbonate.
Bicarbonate infusion. The subjects were allowed to breathe quietly at a PET CO 2 ϳ3 Torr above resting level in normoxia (PET O 2 100 -110 Torr). Then, at this constant PET CO 2 , sodium bicarbonate (8.4%) was infused in a quantity anticipated to change base excess by ϳ5-6 meq/l using the formula dose ϭ 0.3 ϫ body weight ϫ 6. This is based on the assumption that the extracellular fluid is ϳ33% of total body weight (e.g., see Ref. 45) . In most subjects, the infusion lasted 30 -45 min. Between subjects, infused volumes varied between 120 and 180 ml.
Data analysis. At all PET CO 2 levels, breath-to-breath inspired ventilation of the last minute of normoxia and hyperoxia and of the fourth minute of hypoxia were averaged. By plotting ventilation against PET CO 2 , we determined CO2 response curves in terms of slope and x-intercept, using the formula V i ϭ S(PCO2 Ϫ B), where S ϭ total ventilatory CO2 sensitivity (unit l ⅐ min Ϫ1 ⅐ Torr Ϫ1 ) and B ϭ the extrapolated Pa CO 2 at zero ventilation (apnoeic threshold; unit Torr).
As outlined above, hypoxic steps were performed starting from a mild hyperoxic level. It is our experience that mild hyperoxia can cause a small rise in ventilation, possibly due to a diminished Haldane effect and/or a small decrease in cerebral blood flow (e.g., Ref. 7) . Consequently, the difference between hyperoxic and hypoxic ventilation can be smaller than that between normoxic and hypoxic ventilation. Therefore, to limit underestimation of the contribution of the carotid bodies to the initial increase in ventilation during the first 3 min of hypoxia, we considered the difference in ventilation between normoxic and hypoxic ventilation as the response mediated by the carotid bodies. Normoxic levels of ventilation were those obtained over the last minute of normoxia immediately preceding the mild hyperoxic step (Fig. 1 , C, F, and I). In placebo, hypoxic sensitivity was first defined as
. Then, hypoxic sensitivity was plotted as a function of arterial [H ϩ ] measured at the three isocapnic Pa CO 2 levels. Subsequently, the ratio [Vi (hypoxia) Ϫ Vi (normoxia)]/[logPa O 2 (hypoxia) Ϫ log Pa O 2 (normoxia)] was taken as a measure of hypoxic sensitivity; also, this ratio was plotted as a function of arterial [H ϩ ] at the three isocapnic Pa CO 2 levels (note that the normoxic Pa O 2 was always lower than 100 Torr). The relative CO 2-induced changes in hypoxic sensitivities were determined in both cases and appeared to be almost identical (see RESULTS). Therefore, in comparing placebo and metabolic acidosis, hypoxic sensitivities were presented using the ratio ⌬Vi/⌬logPa O 2 , avoiding its possibly erroneous estimation in a condition of metabolic acidosis.
To detect significant effects of acetazolamide on resting parameters and slopes and intercepts of the ventilatory CO 2 response curves, a paired t-test was performed. An analysis of variance was performed on hypoxic sensitivities at different PCO 2 values. Differences between PCO2 were tested with the Student-Newman-Keuls test. P values Ͻ 0.05 were considered significant. Paired comparisons were made (t-tests) in placebo and acetazolamide between relative changes in hypoxic sensitivities, either defined as ⌬V/⌬Sa O 2 or ⌬V/⌬logPa O 2 . Sometimes hypoxic sensitivities were not normally distributed and were indicated. A nonparametric test (Wilcoxon signed-rank test) was used. Unless otherwise indicated, values are means Ϯ SD.
RESULTS
Resting conditions. In accordance with previous studies (38, 41) , acetazolamide induced a metabolic acidosis and a significant rise in mean resting ventilation coupled to a rise in end-tidal and arterial PO 2 and a fall in arterial and end-tidal PCO 2 (Table 1) .
CO 2 responses in normoxia, hyperoxia, and acute hypoxia. Table 2 summarizes the effect of acetazolamide on the steadystate ventilatory CO 2 response curves during normoxia and mild hyperoxia. In normoxia, acetazolamide shifted the curve to lower PET CO 2 values without changing the slope, an effect expected to result from a metabolic acidosis. In mild hyperoxia, ventilatory CO 2 sensitivity showed a small but significant increase following acetazolamide, whereas the apnoeic threshold (x-intercept extrapolated down to zero ventilation) showed a small significant fall.
Hypoxic sensitivity as ⌬V i /⌬logPa O 2 or ⌬V i /⌬Sa O 2 in placebo and following acetazolamide. Table 3 summarizes the percentages by which hypoxic sensitivity, either defined as ⌬V i /⌬log Pa O 2 or ⌬V i /⌬ Sa O 2 , augmented with a rise in Pa CO 2 . Because following acetazolamide, one subject did not respond to hypoxia at the lowest isocapnic PCO 2 level, we calculated individual hypoxic sensitivities in eight subjects enabling us to perform paired comparisons with t-tests. In placebo, no signif-icant differences were found, so with normal acid base status relative increases in hypoxic sensitivities are the same regardless of how the sensitivity is defined. Following acetazolamide, going from the lowest to the intermediate PCO 2 level, the relative increase in sensitivity was significantly smaller when defined as the ratio ⌬V i /⌬Sa O 2 (Table 3) , an effect that could be anticipated if the HbO 2 saturation curve would undergo a rightward shift due to the acidosis, thus resulting in an underestimation of hypoxic sensitivity (we were not able to measure P 50 values). The overall (step 133) relative sensitivity was also smaller when defined as ⌬V i /⌬Sa O 2 . So, an absence of a rightward shift of the HbO 2 saturation curve cannot be excluded.
Effect of acetazolamide on the AHR. Because the placebo data showed that hypoxic sensitivity can also be estimated by using ⌬V i /⌬logPa O 2 , we used this ratio in our further data analysis. Figure 1 shows hypoxic experiments in a representative subject at three levels of PET CO 2 . The influence of acetazolamide on hypoxic sensitivity is shown in Fig. 2 . Data points in this figure represent mean values for hypoxic sensitivity defined as ⌬V i /⌬logPa O 2 at three different average arterial H ϩ concentrations obtained by changing Pa CO 2 in eight (43) , the magnitude of the AHR depends on the PCO 2 level at which it is measured; at a fixed PCO 2 , it will be greater after acetazolamide. To investigate if the rightward shift of the hypoxic sensitivity-[H ϩ ] line could, at least partly, be caused by an inhibiting effect of acetazolamide per se rather than by the substantially lower PCO 2 that accompanies the metabolic acidosis, we also measured AHR after infusion of bicarbonate. This resulted in temporary increases in base excess of 6.1 Ϯ 2.0 and 5.9 Ϯ 1.3 meq ⅐l Ϫ1 in placebo and acetazolamide, respectively. During the measurement protocols, slow infusion rates were sometimes maintained to prevent base excess from too quickly restoring to preinfusion level. Figure 3 shows that after bicarbonate infusion, the response lines shifted to lower levels of [H ϩ a ] and that this occurred in an approximately parallel way in placebo but with a decrease in slope after acetazolamide.
DISCUSSION
The main results of this study can be summarized as follows. 1) Acetazolamide caused a partly compensated, metabolic acidosis; 2) in steady state normoxia, the ventilatory CO 2 response curve showed a parallel shift to the left following acetazolamide, consistent with the picture of a metabolic acidosis; in mild hyperoxia, ventilatory CO 2 Possible limitations of the study and methodological considerations. The metabolic acidosis induced by acetazolamide can be considered "classic" in the sense that the normoxic ventilatory CO 2 response curve displayed a parallel shift to the right , which perfectly agrees with a ratio of 0.9 during a partly compensated metabolic acidosis in healthy subjects (10, 24) . However, apart from inducing a metabolic acidosis, acetazolamide may have rather complex effects on both the control of breathing and the volume status of the body, and the present data cannot be discussed without taking these into consideration.
First, acetazolamide is a mild diuretic and will therefore cause extracellular fluid (ECF) volume depletion (3). Both changes in ECF volume and osmolality may have an effect on respiratory control (1, 34) . The effects on volume status appear complex: decrements in total body, and extracellular, water, but an increase in intracellular water without significant changes in plasma osmolality (3) (osmolality in our subjects, calculated as 2 [Na ϩ ] ϩ [glucose]/18 did not change significantly). Assuming no effect of the dose regimen on erythropoietin production and an initial plasma of volume of 5 l, we estimate an ϳ4% volume depletion in our subjects (see Table  1 ). The effects on electrolyte status are also complex: a kaliuretic effect along with an intra-to-extracellular shift of potassium ions and opposite shifts of Na ϩ and H ϩ ions (3). We did not monitor and correct volume status and hence we cannot exclude that changes in water balance may have influenced our results. On the other hand, however, we remark that we were able to reverse the effects of acetazolamide with relatively low volumes of a bicarbonate solution (120 -180 ml), too low to cause appreciable changes in plasma volume. This suggests to us that the parallel shift of the hypoxic sensitivity-[H ϩ a ] line following acetazolamide is due to a pH effect, rather than to changes in volume status of the body.
Second, acetazolamide is a carbonic anhydrase inhibitor that may cause chemical disequilibrium in blood and tissues provided the inhibition of erythrocytic carbonic anhydrase is Ͼ99.95% (28). However, the (clinical) dose that we administered is too low to achieve a fractional inhibition Ͼ0.995, and hence blood gases measured in vitro may be considered to represent in vivo values (28, 36) .
Third, acetazolamide may have inhibitory effects on the hypoxic ventilatory response, but as explained below, we have reasons to believe that these are limited to cases in which it is administered intravenously.
Shortly after bicarbonate infusions, bicarbonate ions will be distributed over the extracellular space tending to restore arterial pH to its preinfusion value. To prevent this from occurring too quickly, infusion rates were sometimes maintained at low rates. This means, steady state in the subjects may not have been reached and the question arises as to how this may have influenced our results. Intra-to-extracellular H ϩ gradients may have been unstable, altering the stimulus level in carotid body cells. However, at least in the placebo condition, CO 2 -induced changes in hypoxic sensitivity were not altered by bicarbonate infusions given the finding that the slopes of the hypoxic sensitivity-[H ϩ ] lines did not obviously change (see Fig. 3 ). Following acetazolamide, the line became less steep after bicarbonate infusion, and it is possible that this is due to less stable H ϩ gradients at the background of a metabolic acidosis. However, an alternative explanation is also possible (see below).
Expressing hypoxic sensitivity as
The difference in ventilation during acute hypoxia and steadystate normoxia was considered to be due to activation of the carotid bodies. The acute hypoxic ventilatory response was defined as the ratio of this difference over ⌬logPa O 2 (both during normoxia and hypoxia blood samples were taken). This does not follow from the conventional exponential relationship between ventilation and Pa O 2 or from the linear ventilationSa O 2 relationship, but was done for practical reasons and based on empirical data in cats (33) . At least in the placebo condition with normal acid-base status, CO 2 Figure 2 shows that at a given Pa CO 2 , the AHR will be greater after acetazolamide; if following acetazolamide administration the hypoxic response is measured at about resting Pa CO 2 , it will be about equal or somewhat lower than at resting Pa CO 2 in placebo, despite the much higher resting [H ϩ ] a (see also Ref. 43) . Thus according to our data, the notion that generally a rise in arterial [H ϩ ] will act to increase the hypoxic response (17, 24) is not tenable. In retrospect, from Fig. 2 we anticipate that this would be unlikely since it would imply an infinitely high AHR in a metabolic acidosis with a pH of ϳ7.30.
Our data do not allow us to draw conclusions as to the mechanism of the O 2 -CO 2 interaction, but they provide some ground for speculation. For example, considering points d and dЈ and e and f in Fig. 3 , hypoxic sensitivity appears to be considerably less at somewhat lower H ϩ a but equal Pa CO 2 levels. Because isocapnic changes in arterial pH penetrate slowly and only partly into the brainstem extracellular space (39), we assume the central chemoreceptor extracellular pH to be about equal in d and dЈ and e and fЈ, respectively. Points dЈ and f are isohydric points, and the lower hypoxic sensitivity in f could be due to the lower carotid body PCO 2 (peripheral O 2 -CO 2 interaction) combined with a diminished efficacy of afferent carotid body output to increase ventilation due to the also lower central PCO 2 (17, 24) , the horizontal shift of the response lines in Fig. 2 after acetazolamide could be due to an inhibitory effect on the carotid bodies without affecting the O 2 -CO 2 interaction. In placebo, bicarbonate shifted the hypoxic sensitivity-[H ϩ ] a response line leftward in an approximately parallel way: the means of the individual slopes were 9.98 Ϯ 1.96 and 9.08 Ϯ 2.30 l ⅐min Ϫ1 ⅐nmol Ϫ1 (P ϭ 0.446) before and after bicarbonate, respectively. Following acetazolamide, the line also shifted leftward, but not without a decrease in slope: the mean of the individual slope decreased from 8.34 Ϯ 1.67 to 5.17 Ϯ 1.09 l⅐ min Ϫ1 ⅐nmol Ϫ1 (P ϭ 0.014). The lower slope after bicarbonate could be related to less stable H ϩ gradients at the background of a metabolic acidosis, so that our measurements would not reflect real steady-state situations. But we also cannot entirely exclude an inhibitory effect of chronic acetazolamide on the carotid bodies. An inhibitory effect, however, is not supported by the finding that both in normoxia and hypoxia acetazolamide increases ventilation (36, 41) . This is clearly different from the effect of intravenous administration in both animals and humans when acetazolamide, in a dose too low to have direct effects on the central nervous system, has inhibitory effects on both the hypoxic response and the O 2 -CO 2 interaction (36, 40, 42) . Why in humans an inhibitory effect seems solely present after acute administration aimed at reaching equal plasma levels of the agent (36) remains unclear. One difference between acute and chronic application is the induction of a metabolic acidosis with the latter. Perhaps for some reason the metabolic acidosis prevents or neutralizes inhibitory effects of acetazolamide on the carotid bodies, and the finding that bicarbonate infusion decreased the slope of the hypoxic sensitivity-[H ϩ ] line could be a manifestation of this. Future studies are warranted to investigate this further. Also, more insight is needed into the mechanism of CO 2 -O 2 interaction in oxygen-sensing (type I) cells in the carotid body and the way in which hypoxia and hypercapnia have more-than-additive effects on Ca 2ϩ influx in type I cells (9, 29) .
Significance for the use of acetazolamide at high altitude. The low Pa CO 2 after chronic acetazolamide will have a stabilizing effect on breathing for at least three reasons that may also play a role in its known beneficial effects on sleep at high altitude. First, if the ventilatory CO 2 response curve shows a parallel leftward shift, the CO 2 reserve, i.e., the difference between the prevailing Pa CO 2 and the Pa CO 2 where apnea ensues (11), will increase. Note that in our study in resting and awake conditions, the difference between the prevailing PCO 2 and apnoeic threshold did not increase, but this was probably due to a small (insignificant) increase in the slope of the ventilatory CO 2 response curve (see the Tables 1 and 2 ). More relevant, however, is what happens during sleep when ventilatory CO 2 sensitivity is reduced resulting in an increase in the CO 2 reserve (11). Second, a lower Pa CO 2 implies a location on a steeper part of the metabolic hyperbola for CO 2 , so that for a given decrease in Pa CO 2 to occur, a larger increase in ventilation is required. And third, the lower Pa CO 2 prevents an enormous increase in hypoxic sensitivity that would occur if H ϩ and CO 2 had no separate effects on the carotid bodies and if hypoxic sensitivity were a unique function of arterial [H ϩ ]. Benzolamide and spironolactone, two diuretic agents that also induce a metabolic acidosis, appeared to reduce periodic breathing during sleep at high altitude and prevented the symptoms of acute mountain sickness, respectively (27, 37) . Thus, acetazolamide's effects at high altitude may at least partly be due to the metabolic acidosis. Further studies are warranted to see if additional effects of acetazolamide, for example on pulmonary vessels (38) , may also contribute to its beneficial effects.
In summary, we showed separate effects of H ϩ and CO 2 on hypoxic sensitivity in humans. Expressing hypoxic sensitivity as ⌬ventilation/⌬logPa O 2 avoids possible confounding influences of changes in position of the HbO 2 saturation curve. With a clinically relevant dosing, acetazolamide has no inhibitory effects on the carotid bodies.
